Valencia Technologies Corporation (“Valencia”), a private medical device company, today announced interim efficacy data from the eCoin Pivotal Clinical Trial will be presented at the upcoming Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) 2020 Annual Meeting to be held from February 25 – 29 in Scottsdale, Arizona
| VALENCIA, Calif., Feb. 27, 2020 /PRNewswire/ -- Valencia Technologies Corporation (“Valencia”), a private medical device company, today announced interim efficacy data from the eCoin Pivotal Clinical Trial will be presented at the upcoming Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) 2020 Annual Meeting to be held from February 25 – 29 in Scottsdale, Arizona. Dr. Alexandra Rogers will be presenting interim 6-month efficacy data from the pivotal study evaluating the use of its eCoin implantable tibial neurostimulator for the treatment of overactive bladder syndrome (OAB) in patients with urgency urinary incontinence.
The study is a prospective, multicenter, single-arm trial to evaluate the safety and effectiveness of tibial nerve stimulation with eCoin in 133 participants. Implanted under local anesthetic in approximately 20 minutes, the eCoin provides automated therapy and eliminates compliance related burdens to patients. The study is designed to evaluate changes from baseline in OAB symptoms as measured by voiding diaries and patient-reported outcomes through 48 weeks of eCoin therapy. Results from the trial will support Valencia’s pre-market approval application to the U.S. Food and Drug Administration upon completion. Oral Presentation Details: About Valencia Contact:
SOURCE Valencia Technologies Corporation |
View original content to download multimedia:
